Funding research to SHUT DOWN the DNA of cancer.
We partnered with researchers from the Shanghai Institute of Hematology to develop the first successful targeted differentiation therapy for acute promyelocytic leukemia (APL) with all-trans-retinoic acid and arsenic trioxide which increased the disease’s five-year survival rate from 25% to 95%.
We pioneered the use of the first successful liver cancer drug treatment through an international consortium led by Mount Sinai.
We created a novel combination of two existing cancer therapies for the treatment of hormone-resistant breast cancer, producing a new clinical trial at several New York hospitals led by Mount Sinai.
We brought together scientists from the Harvard Cancer Center and the Dana-Farber Cancer Institute to develop a targeted therapy for a rare childhood cancer, which is currently in clinical trials.
We advanced the paradigm of treatment for lung cancer by adding targeted drugs to chemotherapy through a collaboration between Dartmouth and Mount Sinai.
What sets us apart? We use our expertise and experience to identify and finance the best minds conducting the latest, cutting-edge cancer research in switching off growth in the cancer genome.